Vaxcyte, Inc. — Director's Dealing 2024

Jan 19, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-01-18

Reporting Person: GUGGENHIME ANDREW (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-01-18	Common Stock	M	8000	$5.35	Acquired	87474	Direct
2024-01-18	Common Stock	S	4387	$60.275	Disposed	83087	Direct
2024-01-18	Common Stock	S	3127	$61.191	Disposed	79960	Direct
2024-01-18	Common Stock	S	463	$61.881	Disposed	79497	Direct
2024-01-18	Common Stock	S	23	$63.35	Disposed	79474	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-18	Stock Option (right to buy)	$5.35	M	8000	Disposed	2030-05-11	Common Stock (8000)	Direct

Footnotes

F1: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $59.77 to $60.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $60.80 to $61.76. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $61.84 to $62.305. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.